Edaravone (TTYP01)

Small molecule

Filedunder review

Evidence outlook · regulatory review

Acute Ischemic Stroke: application under NMPA review

NMPA accepts the marketing application for edaravone tablets (TTYP01) in acute ischemic stroke (Huadong Medicine notice 2025-07-31) (2025-07-31). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Latest reported trial: NCT06648304 · Phase 3 · met primary endpoint · grade pending

Also in development:Alzheimer's Disease · Phase 2

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Acute Ischemic Stroke
Phase 2 (2)
Alzheimer's Disease
Other / comorbidity
NCT06757504 · Shanghai Auzone Biological Technology Co., Ltd.
2025-01-13 – 2026-05-08 · Autism Spectrum Disorder (ASD)
What this study did
Phase 1 (2)
Other / comorbidity
NCT06107205 · Shanghai Auzone Biological Technology Co., Ltd.
2023-11-07 – 2023-12-14 · Healthy Adult Subjects
What this study did
NCT04370431 · Shanghai Auzone Biological Technology Co., Ltd.
2020-04-24 – 2021-01-08 · Healthy Adult Subjects
What this study did

Competitive landscape

This drug's own stage for Acute Ischemic Stroke: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Edaravone (TTYP01): this drugPhase 3Small moleculeoxidative stressnot yet gradedNo reviewed efficacy summary in this indication
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorReliable signal
NCT03354429: Composite of Subsequent Stroke or Death (From randomisation (day 1) to visit 3 (day 30-34)): TICAGRELOR 303 Participants | PLACEBO 362 Participants
Rinvecalinase AlfaPhase 2/3Protein / enzyme therapeuticTissue kallikrein-1 (KLK1)not yet gradedNo reviewed efficacy summary in this indication
Apadamtase Alfa (Adzynma)Phase 2Protein / enzyme therapeuticADAMTS13not yet gradedNo reviewed efficacy summary in this indication
HRS-4029Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
HRS-7450Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
HRS-8829
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Edaravone (TTYP01) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
October 2028 (1)
Phase 2Alzheimer's DiseaseRecruiting
Est. primary completion 2028-10-23 · NCT07252440 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

31 July 2025Filing acceptedNMPA accepts the marketing application for edaravone tablets (TTYP01) in acute ischemic stroke (Huadong Medicine notice 2025-07-31)
CN, NMPA · Shanghai Auzone Biological Technology · Source ↗
30 July 2025Filing acceptedNMPA accepts China marketing application for edaravone tablets (TTYP01) in acute ischemic stroke
China, NMPA · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Source ↗